A Phase 2 interventional study of Venetoclax in Chronic Lymphocytic Leukemia, sponsored by AbbVie. Completed at 15 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-12-19.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 22nd largest by enrollment, is one of 6 that started in 2014, is one of 41 in phase 2, and was the 7th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Kerry Rogers · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
City of Hope Medical Center · Sites in United States
Ages 18+
Zulfa Omer · Sites in United States
Ages 18+
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 44 · Phase 3 15 · Phase 4 1
First in 2011; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 69 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 69 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 16th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2014, is one of 11 in phase 2, and was the 22nd registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
13 of the studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 593 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
Drug: Venetoclax
Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1023 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
Drug: Venetoclax
Participants with ibrutinib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 622 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.
Drug: Venetoclax
Participants with idelalisib-resistant or refractory chronic lymphocytic leukemia (CLL) received venetoclax tablets once daily (QD) until disease progression or study drug discontinuation; median time on treatment was 1189 days. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. Participants enrolled into the Expansion Cohort with bulky disease at study entry who were non-responders or those who showed signs of clinical progression after completing the ramp up to 400 mg either by clinical disease assessment or by CT/MRI scan between Week 6 to Week 12 may have been permitted to escalate venetoclax to a daily dose of 600 mg.
Drug: Venetoclax
Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
Also known as: ABT-199, VENCLEXTA®
Overall Response Rate (ORR)
Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria.
Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Duration of Response (DOR)
DOR is defined as the number of days from the date of first response (complete response \[CR\], complete response with incomplete marrow recovery \[CRi\], nodular partial remission \[nPR\], or partial remission \[PR\]) to the earliest recurrence or progressive disease. DOR was analyzed by Kaplan-Meier (K-M) methodology.
Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Time to Progression (TTP)
TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.
Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Progression-free Survival (PFS)
PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.
Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Overall Survival (OS)
OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.
Time frame: At Wk 5, Day 1; Wk 8, Day 1; Wk 12, Day 1; Wk 16, Day 1; Wk 20, Day 1; Wk 24, Day 1; Wk 36, Day 1; every 12 wks after Wk 36; Final Visit; estimated median time on follow-up was 1694 d for ibrutinib failure cohort and 1942 d for idelalisib failure cohort
Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT)
TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology.
Time frame: Collected every 3 months for a period of 5 years after the last participant had enrolled into the study
Percentage of Participants With Minimal Residual Disease (MRD) Negativity Status
The rate of MRD response is defined as the percentage of participants who had MRD negative status.
Time frame: Assessed at Week 24, Day 1; after the first Complete Response, Complete Remission with Incomplete Marrow Recovery, or Partial Response; at 12-week interval visits until two consecutive negative MRD levels were reported
| Milestone | ABT-199 After Ibrutinib Therapy | ABT-199 After Idelalisib Therapy | ABT-199 After Ibrutinib Therapy: Expansion Cohort | ABT-199 After Idelalisib Therapy: Expansion Cohort |
|---|---|---|---|---|
| Started | 43 | 21 | 48 | 15 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 43 | 21 | 48 | 15 |
| Withdrew: Adverse event, not related to progression | 8 | 1 | 3 | 1 |
| Withdrew: Adverse event, related to progression | 1 | 0 | 2 | 0 |
| Withdrew: Covid-19 infection | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 2 |
| Withdrew: Other, not specified | 14 | 11 | 23 | 9 |
| Withdrew: Progressive disease, richter's | 4 | 1 | 1 | 1 |
| Withdrew: Progressive disease per protocol | 12 | 7 | 9 | 2 |
| Withdrew: Stem cell transplant | 1 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 0 | 0 |
| Withdrew: Subject non-compliance | 0 | 0 | 1 | 0 |
| Withdrew: Withdrew consent | 2 | 0 | 4 | 0 |
Overall response rate is defined as the percentage of participants with an overall response (per the investigator assessment) 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) criteria.
| percentage of participants | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Overall Response Rate (ORR) | 64.8 (54.1 to 74.6) | 69.4 (51.9 to 83.7) |
DOR is defined as the number of days from the date of first response (complete response \[CR\], complete response with incomplete marrow recovery \[CRi\], nodular partial remission \[nPR\], or partial remission \[PR\]) to the earliest recurrence or progressive disease. DOR was analyzed by Kaplan-Meier (K-M) methodology.
| months | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Duration of Response (DOR) | 35.1 (19.4 to 50.5) | 55.4 (32.0 to NA) |
TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.
| months | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Time to Progression (TTP) | 36.1 (21.9 to 49.0) | 43.4 (20.1 to NA) |
PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.
| months | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Progression-free Survival (PFS) | 24.7 (19.2 to 40.9) | 43.4 (20.1 to NA) |
OS is defined as the number of days from the date of first dose to the date of death for all dosed participants. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.
| months | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Overall Survival (OS) | 69.6 (51.3 to NA) | NA (57.2 to NA) |
TNNT is defined as the number of days from the date of the first dose of venetoclax to the date of first dose of any non-protocol anti-leukemia therapy (NPT) or death from any cause. For participants who did not take NPT, their data was censored at the last known date to be free of NPT. TTNT was analyzed by Kaplan-Meier methodology.
| months | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Time to Next Anti-Chronic Lymphocytic Leukemia Treatment (TNNT) | 24.0 (18.7 to 40.9) | 37.8 (17.1 to NA) |
The rate of MRD response is defined as the percentage of participants who had MRD negative status.
| percentage of participants | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts |
|---|---|---|
| Peripheral blood | 30.8 (21.5 to 41.3) | 25.0 (12.1 to 42.2) |
| Bone marrow | 6.6 (2.5 to 13.8) | 11.1 (3.1 to 26.1) |
Collected over All-cause mortality reported from enrollment to 30 d after last dose of study drug; median time on follow up was up to 1694 d for those with ibrutinib-resistant or refractory CLL and up to 1942 d for those with idelalisib-resistant or refractory CLL. TEAEs and SAEs collected from first dose of study drug until 30 d after last dose of study drug; mean duration on study drug was 819.8 d (ibrutinib-resistant or refractory CLL cohorts) and 1151.5 d (idelalisib-resistant or refractory CLL cohorts).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABT-199 After Ibrutinib Therapy: Main Cohort | 25/43 (58.1%) | 35/43 (81.4%) | 43/43 (100%) |
| ABT-199 After Idelalisib Therapy: Main Cohort | 9/21 (42.9%) | 14/21 (66.7%) | 21/21 (100%) |
| ABT-199 After Ibrutinib or Idelalisib Therapy: Main Cohort | 34/64 (53.1%) | 49/64 (76.6%) | 64/64 (100%) |
| ABT-199 After Ibrutinib Therapy: Expansion Cohort | 17/48 (35.4%) | 26/48 (54.2%) | 48/48 (100%) |
| ABT-199 After Idelalisib Therapy: Expansion Cohort | 4/15 (26.7%) | 9/15 (60%) | 15/15 (100%) |
| ABT-199 After Ibrutinib or Idelalisib Therapy: Expansion Cohort | 21/63 (33.3%) | 35/63 (55.6%) | 63/63 (100%) |
| ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | 42/91 (46.2%) | 61/91 (67%) | 91/91 (100%) |
| ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | 13/36 (36.1%) | 23/36 (63.9%) | 36/36 (100%) |
| All Participants | 55/127 (43.3%) | 84/127 (66.1%) | 127/127 (100%) |
| Event | ABT-199 After Ibrutinib Therapy: Main Cohort | ABT-199 After Idelalisib Therapy: Main Cohort | ABT-199 After Ibrutinib or Idelalisib Therapy: Main Cohort | ABT-199 After Ibrutinib Therapy: Expansion Cohort | ABT-199 After Idelalisib Therapy: Expansion Cohort | ABT-199 After Ibrutinib or Idelalisib Therapy: Expansion Cohort | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | All Participants |
|---|---|---|---|---|---|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 10/43 | 1/21 | 11/64 | 3/48 | 0/15 | 3/63 | 13/91 | 1/36 | 14/127 |
| PNEUMONIAInfections and infestations | 6/43 | 3/21 | 9/64 | 3/48 | 1/15 | 4/63 | 9/91 | 4/36 | 13/127 |
| SEPSISInfections and infestations | 0/43 | 0/21 | 0/64 | 1/48 | 2/15 | 3/63 | 1/91 | 2/36 | 3/127 |
| PYREXIAGeneral disorders | 0/43 | 2/21 | 2/64 | 2/48 | 1/15 | 3/63 | 2/91 | 3/36 | 5/127 |
| INFLUENZAInfections and infestations | 0/43 | 2/21 | 2/64 | 0/48 | 0/15 | 0/63 | 0/91 | 2/36 | 2/127 |
| ANAEMIABlood and lymphatic system disorders | 0/43 | 0/21 | 0/64 | 1/48 | 1/15 | 2/63 | 1/91 | 1/36 | 2/127 |
| ATRIAL FLUTTERCardiac disorders | 0/43 | 0/21 | 0/64 | 0/48 | 1/15 | 1/63 | 0/91 | 1/36 | 1/127 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/43 | 0/21 | 0/64 | 0/48 | 1/15 | 1/63 | 0/91 | 1/36 | 1/127 |
| CHEST PAINGeneral disorders | 0/43 | 0/21 | 0/64 | 1/48 | 1/15 | 2/63 | 1/91 | 1/36 | 2/127 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROMEGeneral disorders | 1/43 | 1/21 | 2/64 | 0/48 | 1/15 | 1/63 | 1/91 | 2/36 | 3/127 |
| Event | ABT-199 After Ibrutinib Therapy: Main Cohort | ABT-199 After Idelalisib Therapy: Main Cohort | ABT-199 After Ibrutinib or Idelalisib Therapy: Main Cohort | ABT-199 After Ibrutinib Therapy: Expansion Cohort | ABT-199 After Idelalisib Therapy: Expansion Cohort | ABT-199 After Ibrutinib or Idelalisib Therapy: Expansion Cohort | ABT-199 After Ibrutinib Therapy: Main and Expansion Cohorts | ABT-199 After Idelalisib Therapy: Main and Expansion Cohorts | All Participants |
|---|---|---|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 24/43 | 6/21 | 30/64 | 30/48 | 4/15 | 34/63 | 54/91 | 10/36 | 64/127 |
| NEUTROPENIABlood and lymphatic system disorders | 16/43 | 10/21 | 26/64 | 20/48 | 9/15 | 29/63 | 36/91 | 19/36 | 55/127 |
| ANAEMIABlood and lymphatic system disorders | 24/43 | 4/21 | 28/64 | 21/48 | 3/15 | 24/63 | 45/91 | 7/36 | 52/127 |
| DIARRHOEAGastrointestinal disorders | 22/43 | 9/21 | 31/64 | 26/48 | 8/15 | 34/63 | 48/91 | 17/36 | 65/127 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 15/43 | 9/21 | 24/64 | 19/48 | 7/15 | 26/63 | 34/91 | 16/36 | 50/127 |
| FATIGUEGeneral disorders | 20/43 | 7/21 | 27/64 | 22/48 | 3/15 | 25/63 | 42/91 | 10/36 | 52/127 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 20/43 | 1/21 | 21/64 | 12/48 | 2/15 | 14/63 | 32/91 | 3/36 | 35/127 |
| PLATELET COUNT DECREASEDInvestigations | 19/43 | 1/21 | 20/64 | 11/48 | 4/15 | 15/63 | 30/91 | 5/36 | 35/127 |
| WHITE BLOOD CELL COUNT DECREASEDInvestigations | 18/43 | 2/21 | 20/64 | 16/48 | 3/15 | 19/63 | 34/91 | 5/36 | 39/127 |
| OEDEMA PERIPHERALGeneral disorders | 8/43 | 6/21 | 14/64 | 18/48 | 1/15 | 19/63 | 26/91 | 7/36 | 33/127 |
All treated participants
| Age, Continuous(years) | ABT-199 After Ibrutinib Therapy | ABT-199 After Idelalisib Therapy | ABT-199 After Ibrutinib Therapy: Expansion Cohort | ABT-199 After Idelalisib Therapy: Expansion Cohort | Total |
|---|---|---|---|---|---|
| Mean | 65.7 ± 8.74 | 68.0 ± 7.26 | 64.2 ± 10.72 | 68.7 ± 8.35 | 65.9 ± 9.34 |
| Sex: Female, Male(Participants) | ABT-199 After Ibrutinib Therapy | ABT-199 After Idelalisib Therapy | ABT-199 After Ibrutinib Therapy: Expansion Cohort | ABT-199 After Idelalisib Therapy: Expansion Cohort | Total |
|---|---|---|---|---|---|
| Female | 10 | 6 | 17 | 5 | 38 |
| Male | 33 | 15 | 31 | 10 | 89 |
| Race/Ethnicity, Customized(Participants) | ABT-199 After Ibrutinib Therapy | ABT-199 After Idelalisib Therapy | ABT-199 After Ibrutinib Therapy: Expansion Cohort | ABT-199 After Idelalisib Therapy: Expansion Cohort | Total |
|---|---|---|---|---|---|
| White | 40 | 19 | 45 | 13 | 117 |
| Black | 2 | 2 | 3 | 1 | 8 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| American Indian/Alaska native | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 |
| Multi race | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Sep 2014 to primary completion in Dec 2021, 87 months.
Results were first posted in Dec 2022, 11 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 87 months is above that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →